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Low Yield of Methicillin-Resistant Staphylococcus aureus Screening in
Hemodialysis Patients: 10 Years’ Experience
H. M. Gebreselassie, MD;1 T. Kaspar, RN;1 S. Droz, PhD;2 J. Marschall, MD1
objective. To determine the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in hemodialysis patients
and to analyze the cost-effectiveness of our screening approach compared with an alternative strategy.
design. Screening study and cost-effectiveness analysis.
methods. Analysis of twice-yearly MRSA prevalence studies conducted in the hemodialysis unit of a 950-bed tertiary care hospital from
January 1, 2004, through December 31, 2013. For this purpose, nasal swab samples were cultured on MRSA screening agar (mannitol-oxacillin
biplate).
results. There were 20 mass screenings during the 10-year study period. We identiﬁed 415 patients participating in at least 1 screening, with
an average of 4.5 screenings per patient. Of 415 screened patients, 15 (3.6%) were found to be MRSA carriers. The ﬁrst mass screening in 2004
yielded the highest percentage of MRSA (6/101 [6%]). Only 7 subsequent screenings revealed new MRSA carriers, whereas 4 screenings
conﬁrmed previously known carriers, and 8 remained negative. None of the carriers developed MRSA bacteremia during the study period. The
total cost of our screening approach, that is, screening and isolation costs, was US $93,930. The total cost of an alternative strategy (ie, no mass
screening administered) would be equivalent to costs of isolation of index cases and contact tracing was estimated to be US $5,382 (difference,
US $88,548).
conclusions. In an area of low MRSA endemicity (<5%), regular nasal screenings of a high-risk population yielded a low rate of MRSA
carriers. Twice-yearly MRSA screening of dialysis patients is unlikely to be cost-effective if MRSA prevalence is low.
Infect Control Hosp Epidemiol 2015;00(0) :1–4
Infections are a leading cause of hospitalization, loss of vas-
cular access (catheter or arteriovenous ﬁstula), and death in
hemodialysis patients. Many infections but not all are
hemodialysis catheter–associated infections and are caused
by gram-positive cocci such as Staphylococcus aureus.1,2
Methicillin-susceptible S. aureus and methicillin-resistant
S. aureus (MRSA) are the most common pathogens3 and
may cause a wide array of infections. Colonization with
S. aureus is a prerequisite for subsequent infection.4–6
Screening for MRSA is therefore a key component of
successful infection control strategies in that it identiﬁes
asymptomatic reservoirs of MRSA relevant for transmission.7
Screening has been used to assess the burden of MRSA
carriage in hemodialysis patients prior to interventions.
The aim of our study was to determine the prevalence of
MRSA nasal colonization in hemodialysis patients and to
analyze the cost-effectiveness of our screening approach
compared with an alternative strategy in which no mass
screenings would be conducted.
methods
Setting and Infection Prevention Strategies
The University Hospital of Bern, Switzerland, is a tertiary care
hospital with 950 beds. The mass screening studies were con-
ducted in the hemodialysis unit from January 1, 2004, through
December 31, 2013. This unit accommodates 30 patients
per day in a single, large treatment room, with dialysis sessions
divided into morning and afternoon sessions. One nurse is
responsible for 5 patients undergoing hemodialysis at a time.
Our MRSA policy included, ﬁrst, screening of high-risk
groups, such as hemodialysis patients and patients who were
transferred from hospitals with high MRSA prevalence in the
previous 6 months. Second, there were contact precautions for
all MRSA colonized/infected patients with placement in single
rooms, and use of a door sign, gowns, and gloves in addition to
standard precautions. Precautions were discontinued once a
patient had 3 consecutive negative results for MRSA during
9 months of follow-up. Third, contact screening was
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conducted for inpatients who shared the same ward with a
newly identiﬁed MRSA carrier at the time of diagnosis and for
those who had been concurrently hospitalized with the index
case during the previous 12 months.
No decolonization methods were used for any of the MRSA
carriers identiﬁed in hemodialysis screenings.
Data Collection, Laboratory Method, and Data Analysis
We determined the prevalence of MRSA in dialysis patients
during twice-yearly mass screenings for the years 2004–2013.
Demographic data including sex and age were collected for
each patient during screening session. For laboratory purposes,
we obtained NaCl 0.9% wet cotton nasal swabs, which were
circled in both nares of a participant. The samples were then
placed into the transport medium (Copan Transystem)
immediately. The samples were cultured on a screening agar
for MRSA (mannitol-oxacillin biplate). Identiﬁcation was
performed according to standard laboratory procedures.
Susceptibility testing was performed using disk diffusion tests
and the results were interpreted according to the Clinical and
Laboratory Standards Institute. For determining methicillin
resistance we used oxacillin disks.
Those patients who had at least one positive nasal
MRSA culture were deﬁned as MRSA carriers, whereas all
patients with negative MRSA culture results were regarded as
noncarriers. We determined the yield of each screening and
the overall yield and expressed it as a percentage.
Cost Analysis
We compared the cost of our MRSA prevention strategy with
a scenario where no active screening of MRSA carriage is
performed on a routine basis (ie, the alternative strategy).
The current strategy has 2 major contributors of cost, which
are mass screening and isolation of carriers. In contrast, the
alternative strategy would generate cost due to the isolation of
infected patients and screening of their contacts.
The screening program cost itself consists of the cost of the
swab material and laboratory processing. The cost of contact
precautions was calculated as cost of gloves, gowns, and
handrub bottles and included the terminal cleaning of single
rooms where carriers are isolated.
In the alternative strategy, in order to calculate the contact tra-
cing costs, we assumed that the rate of hospital admission of uni-
dentiﬁed MRSA carriers among hemodialysis patients would be
similar to what we found in colonized patients over 10 years (see
Results section). Of the 15MRSA carriers among 415 hemodialysis
patients, 13 [86.7%] would have been admitted under that
assumption. According to the literature, MRSA carriage has a 33%
likelihood of progressing to infection in the year after detection of
colonization.8 We took this percentage to calculate the number of
MRSA-colonized, hospitalized hemodialysis patients who would
progress to MRSA infection—that is, 5 of the 13 admitted colo-
nized patients. Per our MRSA policy these 5 index patients would
have required isolation, thus generating cost for contact
precautions. Owing to the lack of accurate information on inpa-
tient acquisition of MRSA in our hospital, we used the overall
prevalence of MRSA from our screening study—that is, 3.6%, as a
surrogate for the MRSA acquisition rate in hospitalized patients.
These 5 MRSA-infected patients would be index cases to start
MRSA contact screening. The average number of patients included
in the contact tracing of an index case is 17 (range, 1–66) (infor-
mation taken from unpublished MRSA contact tracing data of the
hospital in the same study period). This subsequently led us to
estimate the cost of contact tracing, which shares variables with
cost of screening—that is, cost of swab transport system and
laboratory processing costs for 85 (5 times 17) exposed patients.
results
There were 20 mass screenings during the 10-year study per-
iod. We identiﬁed 415 hemodialysis patients who participated
in at least 1 screening, with an average of 4.5 screenings per
patient. On average, 90 samples were taken at each mass
screening. Overall, a total of 1,901 individual nasal swab
samples were taken, among which 22 (1.2%) were positive for
MRSA (Figure 1). These 22 positive swab samples were
obtained from 15 patients. Of the total 415 screened individual
hemodialysis patients, 15 (3.6%) were found to be MRSA
carriers. One patient had 5, and 3 patients each had 2, MRSA
positive nasal swabs in different screening sessions.
The ﬁrst mass screening, in 2004, yielded the highest
percentage of MRSA carriage (6/101 [6%]). Only 7 subsequent
screenings revealed new MRSA carriers, whereas 4 screenings
simply conﬁrmed previously known carriers, and 8 screenings
remained negative.
Men were predominant among the MRSA carriers
(20/22 [91%]). Twenty of the 22 positive swabs came from
ﬁgure 1. Methicillin-resistant staphylococcus aureus prevalence in
hemodialysis patients at Bern University Hospital from January 1,
2004, through December 31, 2013. Screening occurred twice yearly;
the number of the screening follows the year on the x-axis. The
number of samples collected at each screening is indicated on the
y-axis. NEG, negative; POS, positive.
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patients aged more than 65 years, which represented the largest
age group of participants (53%).
From our MRSA follow-up data, we were able to extract the
median duration of MRSA carriage in 12 of these patients; it
was 7 months (range, 3–23 months). Two patients had inter-
mittent colonization and for another one, no follow-up data
was available. None of the identiﬁed MRSA carriers developed
MRSA bacteremia during the study period. We have found
that in the 15MRSA carriers, 13 underwent hospital admission
at our center over a 10-year period.
The current laboratory cost for processing a negative sample
is approximately US $42 and for a positive sample US $50. The
total screening costs inclusive of the swab material for the 20
screenings were estimated to be US $89,266 in 2014; the
average cost for identifying each of the 15 MRSA carriers was
US $5,951. The cost of contact precautions for 13 patients who
were admitted was calculated to be US $4,664. The total cost of
our screening strategy, which is the sum of screening cost and
isolation cost, was US $93,930 (Table 1).
The total cost of the alternative strategy (based on assump-
tions) would be equivalent to the cost for contact tracing
performed on 85 patients, which would be US $3,969, and for
isolation of 5 MRSA-infected cases equaling US $1,413 (ie, a
total of 5 MRSA-infected patients and their 85 contacts),
resulting in a total of US $5,382. This results in a difference of
US $88,548 between the 2 strategies.
discussion
Screening and isolation, with or without efforts to eradicate
carriage, have been associated with fewer secondary MRSA
transmissions and a decreased rate of MRSA bacteremia.9
Starting in 2004, we found the overall prevalence of MRSA
colonization in hemodialysis patients over the 2004–2013 decade
to be low at 3.6% (or 1.2% of all specimens obtained). At that
time, the proportion of all S. aureus isolates from clinical speci-
mens that was MRSA was approximately 8% for the entire
country of Switzerland, varying from 4% in central to 14% in
western Switzerland.10 The fact that our institution is situated in
an area of low MRSA prevalence (<5%) coincides with the
results reported here. A screening study by Bühlmann et al7 in
the same institution, which was performed on 236 patients who
had contact with aMRSA patient in the hospital or were transfers
from high-prevalence areas from other parts of Switzerland,
yielded a 1.7% carriage rate (ie, 4 patients were positive). This
suggests that our hemodialysis patients had a higher risk of
MRSA colonization compared with a general patient population.
To date, a number of studies have focused on catheter site
application of mupirocin11 and nasal decolonization in the
prevention of bloodstream infection in hemodialysis
patients.3,4,12,13 Our study differs from these studies in that it
addresses screening and isolation measures in the control of
MRSA only in hemodialysis patients.
Although we lack information on subsequent rates of MRSA
infection other than bacteremia, there were no bacteremia
cases reported in our MRSA-colonized hemodialysis patients
in the study period. Other studies have found that a substantial
proportion of patients who develop MRSA infection following
colonization develop pneumonia, wound infections, and
others.8,14 Patients may still have presented to an outside
hospital with MRSA infection, however.
We also determined the median time until MRSA clearance
to be 7 months. This ﬁnding is in agreement with an earlier
study in our hospital aiming to examine the duration of MRSA
carriage, its determinants, and the inﬂuence of an eradication
regimen performed on 116 patients (including but not limited
to those on hemodialysis), which revealed the median time to
clearance to be 7.4 months.15 Because no decolonization
regimes were administered during the study period, we cannot
estimate what marginal beneﬁt in reducing MRSA infection
such a strategy might have achieved.
Currently, there are no universal guidelines for hospital
control of MRSA. Various hospitals and countries have used
their own practices to suit their needs and resources.
Given the low rate of carriage and the high cost of our MRSA
screening strategy in hemodialysis patients, we questioned the cost-
effectiveness of such a strategy in a low-prevalence area. A cost
comparison of MRSA screening and management in a decision
tree study showed that, at a lowMRSA prevalence, “no screening”
produces costs comparablewith targeted screening strategies. Costs
for targeted screening become disproportionately high as MRSA
prevalence increases.16 The prevalence of MRSA colonization
table 1. Cost Comparison Between Screening and Alternative
Strategy
Cost variable
Cost of current screening
strategy (US$)
Cost of alternative
strategy (US$)
Screening cost
Transport
media cost
801 …
Laboratory
processing
cost
88,465 …
Isolation cost 4,664 1,413
Contact tracing cost
Transport
media cost
… 35
Laboratory
processing
cost
… 3,934
Total 93,930 5,382
NOTE. Laboratory processing cost includes both negative and positive
samples. Cost of isolation: estimated 100 encounters of nurses per 1
isolated patient and hand hygiene compliance 80% using 5 mL per
rub that costs US $1.03 per 100 mL handrub (5.15 cents per indica-
tion)=US $4.12; use of gloves per indication 5 contacts with 5 glove
indications each, resulting in 25 glove indications per day (4.12 cents
per glove)=US $1.03; use of gown 20 indications per day (US $1.40
per gown)=US $28; cleaning of positive room=US $11.9; average
estimated stay of an isolated patient= 10 days.
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therefore exerts a signiﬁcant inﬂuence on the choice of the optimal
preventive strategy. As reported here, there is a signiﬁcant
difference of US $88,548 for the entire study period between our
relatively costly current screening strategy and an alternative
strategy, which is based on certain assumptions.
Although a study in another Swiss tertiary hospital that
examined MRSA admission screening of patients in a low-
prevalence setting concluded that, in terms of cost-effective-
ness, individualized (or targeted) screening strategies seem to
be more favorable in a low-prevalence setting,17 our results
showed that such a conclusion needs to be further studied.
Limitations of the study include the single-center setting
and that risk factors for MRSA colonization were not identiﬁed
in detail in our patients. It is also possible that we missed
colonization of body sites other than the anterior nares. Geno-
typing was not performed, likewise, and we cannot distinguish
whether the 4 patients who tested positive on more than one
occasion were recolonizations by the same strain or acquired a
new one.18
Although the role of decolonization treatment in controlling
MRSA is controversial, with some studies showing no effect, oth-
ers have reported a decrease in subsequent infection rates.19 There
were no decolonization attempts in our MRSA carrier population.
We also did not determine overall crude mortality.
We conclude that, in an area of low prevalence, it would be
cost saving to discontinue mass screenings and instead to con-
centrate on tracing contacts of newly identiﬁed MRSA-infected
hemodialysis patients. As a ﬁrst step, we reduced mass screening
from twice yearly to once yearly in our institution. Future studies
may help determine the most cost-effective strategy for MRSA
prevention in hemodialysis patients or other high-risk popula-
tions as a function of the local prevalence.
acknowledgments
We are indebted to the entire infection prevention team for their assistance in
the study. Our special thanks go to Silvia Andrist and Alexia Cusini, MD, for
reviewing the manuscript.
Financial support. None reported.
Potential conﬂicts of interest. All authors report no conﬂicts of interest rele-
vant to this study.
Address correspondence to H. M. Gebreselassie, MD, Department of
Infectious Diseases, Bern University Hospital and University of Bern, Bern,
Switzerland, Freiburgstrasse 18, 3010 Bern, Switzerland (Hiwotmamo.
gebreselassie@insel.ch).
references
1. BC Provincial Renal Agency. Approach to managing antibiotic
resistant organisms (AROs) in British Columbia hemodialysis
units. http://www.bcrenalagency.ca/sites/default/ﬁles/documents/
ﬁles/BCPR-position-paper-AROs-hemodialysis-FINAL.pdf. Updated
June 2009.
2. Parker MG, Doebbeling BN. The challenge of methicillin-
resistant Staphylococcus aureus prevention in hemodialysis ther-
apy. Semin Dial 2012;25:42–49.
3. Kang YC, Tai WC, Yu CC, Kang JH, Huang YC. Methicillin-
resistant Staphylococcus aureus nasal carriage among patients
receiving hemodialysis in Taiwan: prevalence rate, molecular
characterization and de-colonization. BMC Infect Dis 2012;12:284.
4. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG,
D’Agata EMC. Mupirocin prophylaxis to prevent Staphylococcus
aureus infection in patients undergoing dialysis: a meta-analysis.
Clin Infect Dis 2003;37:1629–1638.
5. Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E.
Meta-analysis of methicillin-resistant Staphylococcus aureus
colonization and risk of infection in dialysis patients. J Am Soc
Nephrol 2014;25:2131–2141.
6. Lai CF, Liao CH, Pai MF, et al. Nasal carriage of methicillin-
resistant Staphylococcus aureus is associated with higher all-cause
mortality in hemodialysis patients. Clin J Am Soc Nephrol
2011;6:167–174.
7. Bühlmann M, Bögli-Stuber K, Droz S, Mühlemann K. Rapid
screening for carriage of methicillin-resistant Staphylococcus
aureus by PCR and associated costs. J Clin Microbiol
2008;46:2151–2154.
8. Huang SS, Hinrichsen VL, Datta R, et al. Methicillin-resistant
Staphylococcus aureus infection and hospitalization in high-risk
patients in the year following detection. PLOS ONE 2011;6:e24340.
9. Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization
associated withmethicillin resistance for patients with Staphylococcus
aureus infection. Infect Control Hosp Epidemiol 2010;31:365–373.
10. Senn L, Basset P, Greub G, et al. Molecular epidemiology of
methicillin-resistant Staphylococcus aureus in Switzerland:
sampling only invasive isolates does not allow a representative
description of the local diversity of clones. Clin Microbiol Infect
2013;19:E288–E290.
11. McCann M, Moore ZE. Interventions for preventing infectious
complications in haemodialysis patients with central venous
catheters. Cochrane Database Syst Rev 2010:CD006894.
12. Lederer SR, Riedelsdorf G, Schifﬂ H. Nasal carriage of meticillin
resistant Staphylococcus aureus: the prevalence, patients at risk
and the effect of elimination on outcomes among outclinic hae-
modialysis patients. Eur J Med Res 2007;127:284–288.
13. Resić H, Corić A, Dedeić-Ljubović A, Hukić M, Avdić E,
Kukavica N. Prevalence of MRSA infections in patients on
hemodialysis [article in Serbian]. Med Pregl 2007;60:97–100.
14. Dantes R, Mu Y, Belﬂower R, et al. National burden of invasive
methicillin-resistant Staphylococcus aureus infections, United
States, 2011. JAMA Intern Med 2013;173:1970–1978.
15. Marschall J, Mühlemann K. Duration of methicillin-resistant
Staphylococcus aureus carriage, according to risk factors for
acquisition. Infect Control Hosp Epidemiol 2006;27:1206–1212.
16. Tübbicke A, Hübner C, Hübner N-O, Wegner C, Kramer A,
Fleßa S. Cost comparison ofMRSA screening andmanagement—
a decision tree analysis. BMC Health Serv Res 2012;12:438.
17. Witteck A, Rettenmund G, Schlegel M. MRSA admission
screening in a low prevalence setting—much ado about nothing?
Swiss Med Wkly 2011;141:w13217.
18. Price A, Sarween N, Gupta I, Baharani J. Meticillin-resistant
Staphylococcus aureus and meticillin-susceptible Staphylococcus
aureus screening in a cohort of haemodialysis patients: carriage,
demographics and outcomes. J Hosp Infect 2015;90:22–27.
19. Kohler P, Bregenzer-Witteck A, Rettenmund G, Otterbech S,
Schlegel M. MRSA decolonization: success rate, risk factors for
failure and optimal duration of follow-up. Infection 2013;41:33–40.
4 infection control & hospital epidemiology
